Digestive Diseases and Sciences

, Volume 46, Issue 9, pp 1924–1936 | Cite as

Prevention of Acute NSAID-Related Gastroduodenal Damage: A Meta-Analysis of Controlled Clinical Trials

  • Gioacchino Leandro
  • Alberto Pilotto
  • Marilisa Franceschi
  • Tosca Bertin
  • Emanuela Lichino
  • Francesco Di Mario
Article

Abstract

No consensus exists as to whether cotherapy is effective in the short-term prevention of severe NSAID-related gastroduodenal damage. The aim of this study was to provide a quantitative systematic review of the efficacy of gastroprotective drugs, such as misoprostol, H2-blockers, and proton pump inhibitors (PPI) in preventing the severe acute NSAID-related gastroduodenal damage. Placebo-controlled randomized clinical trials on the use of misoprostol, H2-blockers, and PPIs as preventative agents published between January 1986 and May 1999 were identified through Medline and reference lists from clinical reviews. Studies on patients or healthy subjects were considered to be eligible for data pooling if they were performed in acute NSAID users (not longer than 30 days) and with at least one endoscopic evaluation during therapy that reported results specifically for gastric and duodenal damage. Risk difference (RD), heterogeneity χ2 test, publication bias assessment and number needed to treat (NnT) were calculated for each meta-analysis by a customized program. Twenty-one trials met the inclusion criteria evaluating a total of 636 healthy subjects and 1904 patients with arthritis randomized to active drug or placebo. The baseline risk of NSAID-related gastric (68% vs 16.6%, P < 0.001) and duodenal (22% vs 8.5%, P < 0.001) damage was higher in healthy subjects compared to patients with arthritis. Meta-analysis demonstrated a significant heterogeneity between trials performed in the two populations (P < 0.0001). In healthy subjects the active drug treatment induced a significant prevention of severe gastric (misoprostol RD = 69%, 95% CI = 60.3–77.7, H2-blocker RD = 38.3%, 95% CI = 17.8–58.9 and PPI RD = 43%, 95% CI = 28.2–57.7) and duodenal damage (misoprostol RD = 22.3%, 95% CI = 13.6–31, H2-blocker RD = 13.2%, 95% CI = 5.2–21.3 and PPI RD = 17.7%, 95% CI = 3.5–31.8). NnT values were, respectively, 1, 3, and 2 for gastric and 4, 8, and 6 for duodenal damage. In patients with arthritis lower RD and higher NnT values were found compared to healthy subjects. In conclusions, cotreatment with gastroprotective drugs for short-term prevention of severe gastroduodenal NSAID-related damage was more effective in healthy subjects than in patients with arthritis; misoprostol and PPIs were more effective than H2-blockers in the prevention of both gastric and duodenal severe damage; more studies need to evaluate the role of short-term prevention in patients with arthritis who require acute NSAID treatment.

NSAIDs gastroduodenal damage damage prevention meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 340:1888–1899, 1999Google Scholar
  2. 2.
    Beard K, Walker AM, Poerera DR, Jick H: Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med 147:1621–1623, 1987Google Scholar
  3. 3.
    LaPorte JR, Carnè X, Vidal X, Moreno V, Juan J: Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 337:85–89, 1991Google Scholar
  4. 4.
    Pilotto A, Franceschi M, Leandro G, Di Mario F, Valerio G: The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. Eur J Gastroenterol Hepatol 9:951–956, 1997Google Scholar
  5. 5.
    Pilotto A, Leandro G, Di Mario F, Franceschi M, Bozzola L, Valerio G: Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study. Dig Dis Sci 42:586–591, 1997Google Scholar
  6. 6.
    Kemppainen H, Raiha I, Sourander L: Clinical presentation of bleeding peptic ulcer in the elderly. Aging Clin Exp Res 8:184–188, 1996Google Scholar
  7. 7.
    Silverstein FE, Graham DY, Senior JR, et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs: a randomized, double blind, placebo-controlled trial. Ann Intern Med 123:241–249, 1995Google Scholar
  8. 8.
    Hudson N, Taha AS, Russel RI, et al: Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drugassociated gastroduodenal ulceration. Gastroenterology 112:1817–1822, 1997Google Scholar
  9. 9.
    Cullen D, Bardhan KD, Eisner M, et al: Primary gastroduonal prophylaxis with omeprazole for non-steroidal antiinflammatory drug users. Aliment Pharmacol Ther 12:135–140, 1998Google Scholar
  10. 10.
    Yeomans ND, Karrash JA, Szczepanski L, et al: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 338:719–726, 1998Google Scholar
  11. 11.
    Hawkey CJ, Karrasch JA, Szczepanski L, et al: Omperazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338:727–734, 1998Google Scholar
  12. 12.
    Stalnikowicz R, Rachmilewitz D: NSAID-induced gastroduodenal damage: Is prevention needed? A review and metaanalysis. J Clin Gastroenterol 17:238–243, 1993Google Scholar
  13. 13.
    Koch M, Dezi A, Ferrario F, Capurso L: Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 156:2321–2332, 1996Google Scholar
  14. 14.
    Lanza FL, Royer GL, Nelson RS: Endoscopic evaluation of the effects of aspirin, buffered aspirin and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 303:136–138, 1980Google Scholar
  15. 15.
    Leandro G: Meta Analysis. The Handbook for the Understanding and Practice of Meta-Analysis. 2000 (in press), www.media.it/metaGoogle Scholar
  16. 16.
    Galbraith RF: A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894, 1988Google Scholar
  17. 17.
    Di Mario F, Battaglia G, Leandro G, Grasso G, Vianello F, Vigneri S: Short-term treatment of gastric ulcer: Meta-analytic evaluation of blind trials. Dig Dis Sci 41:1108–1131, 1996Google Scholar
  18. 18.
    Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, Lezzi G, Lichino E, Bruno F, Perri F: Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Phamacol Ther 12:237–245, 1998Google Scholar
  19. 19.
    Goulis J, Leandro G, Borroughs AK: Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 354:1053–1060, 1999Google Scholar
  20. 20.
    Rosental R: The ‘file-drawer problem’ and tolerance for null results. Psychol Bull 86:638–641, 1979Google Scholar
  21. 21.
    Klein S, Simes J, Blackbum GL: Total parenteral nutrition nad cancer clinical trials. Cancer 58:1378–1386, 1986Google Scholar
  22. 22.
    Silverstein FE, Kimmey MB, Saunders DR, et al: Gastric protection by misoprostol against 1,300 mg of aspirin. An endoscopic dose-response study. Am J Med 83:32–36, 1987Google Scholar
  23. 23.
    Lanza FK, Aspinall RL, Swabb EA, Davis RE, Rack MF, Rubin A: Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetine-induced mucosal injury to the stomach and duodenum. Gastroenterology 95:289–294, 1988Google Scholar
  24. 24.
    Lanza F, Peace K, Gustitus L, Rack MF, Dickson B: A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 83:143–146, 1988Google Scholar
  25. 25.
    Graham DY, Agrawal NM, Roth SH: Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, doubleblind, placebo-controlled trial. Lancet 2:1277–1280, 1988Google Scholar
  26. 26.
    Jiranek GC, Kimmey MB, Saunders DR, Wilson RA, Shanahan W, Silverstein FE: Misoprostol reduces gastroduodenal injury from one week of aspirin: An endoscopic study. Gastroenterology 96:656–661, 1989Google Scholar
  27. 27.
    Saggioro A, Alvisi V, Blasi A, et al: Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoartritis and rheumatoid artritis. Italian J Gastroenterol 23:119–123, 1991Google Scholar
  28. 28.
    Lanza FL, Kochman RL, Geis GS, Rack EM, Deysach LG: A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits. Am J Gastroenterol 86:1743–1748, 1991Google Scholar
  29. 29.
    Kimmey MB, Silverstein FE, Saunders DR, Chapman RC: Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine. Dig Dis Sci 32:851–856, 1987Google Scholar
  30. 30.
    Berkowitz JM, Rogenes PR, Sharp JT, Warner CW: Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 147:2137–2139, 1987Google Scholar
  31. 31.
    Stalnikowicz R, Pollak D, Eliakim A, et al: Cimetidine decreases indomethacin-induced duodenal mucosal damage in patients with acute musculoskeletal disorders. Gut 29:1578–1582, 1988Google Scholar
  32. 32.
    Ehsanullah RSB, Page MC, Tildesley G, Wood JR: Prevention of gastroduodenal damage induced by non-steroidal antiinflammatory drugs: Controlled trial of ranitidine. Br Med J 297:2017–2021, 1988Google Scholar
  33. 33.
    Stalnikowicz R, Goldin E, Fich A, et al: Indomethacin-induced gastroduodenal damage is not affected by cotreatment with ranitidine. J Clin Gastroenterol 11:178–182, 1989Google Scholar
  34. 34.
    Robinson MG, Griffin JW, Bowers J, et al: Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 34:424–428, 1989Google Scholar
  35. 35.
    Lanza FL, Graham DY, Davis RE, Rack MF: Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 35:1494–1499, 1990Google Scholar
  36. 36.
    Oddsson E, Gudionsson H, Thjodleifsson B: Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 27:1045–1048, 1992Google Scholar
  37. 37.
    Taha AS, Hudson N, Hawkey CJ, et al: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 334:1435–1439, 1996Google Scholar
  38. 38.
    Bergmann JF, Chassany O, Simoneau G, et al: Protection against aspirin-induced gastric lesions by lansoprazole: Simultaneous evaluation of functional and morphologic responses. Clin Pharmacol Ther 52:413–416, 1992Google Scholar
  39. 39.
    Ekstrom P, Carling L, Wetterhus S, et al: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 31:753–758, 1996Google Scholar
  40. 40.
    Piette F, Teillet L Naudin R, et al: Efficacy of misoprostol in the prophylaxis of gastroduodenal lesions induced by shortterm nonsteroidal antiinflammatory drug therapy in elderly patients. A multicenter double-blind, placebo-controlled trial. Rev Rhum (Engl Ed) 64:259–264, 1997Google Scholar
  41. 41.
    Bianchi Porro G, Lazzaroni M, Petrillo M, et al: Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAID treatment. Ital J Gastroenterol Hepatol 30:43–47, 1998Google Scholar
  42. 42.
    Scheiman JM, Behler EM, Loeffler KM, Elta GH: Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 39:97–103, 1994Google Scholar
  43. 43.
    Pilotto A, Di Mario F, Malfertheiner P, Valerio G, Naccarato R: Upper gastrointestinal diseases in the elderly. Eur J Gastroenterol Hepatol 11:801–808, 1999Google Scholar
  44. 44.
    Lipscomb GR, Campbell F, Rees WDW: The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 11:907–912, 1997Google Scholar
  45. 45.
    Larkai EN, Smith JL, Lidsky MD, Graham DY: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82:1153–1158, 1987Google Scholar
  46. 46.
    Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF: Gastrointestinal tract complications of nonsteroidal antiinflammatory drugs treatment in rheumatoid arthritis: Aprospective observational cohort study. Arch Intern Med 156:1530–1536, 1996Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Gioacchino Leandro
    • 1
  • Alberto Pilotto
    • 2
  • Marilisa Franceschi
    • 2
  • Tosca Bertin
    • 2
  • Emanuela Lichino
    • 1
  • Francesco Di Mario
    • 3
  1. 1.Gastroenterological Hospital “S. De Bellis,” IRCCSCastellana Grotte (BA)Italy
  2. 2.Department of GeriatricsDigestive Physiopathology Center for The ElderlyVicenzaItaly
  3. 3.Division of GastroenterologyUniversity of PadovaPadovaItaly

Personalised recommendations